Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Boston Scientific Corporation $BSX Shares Purchased by Assetmark Inc ...

AI-generated analysis

πŸ“ˆ Assetmark Inc. raised its stake in Boston Scientific by 36.9% to own 145,679 shares valued at $9.14 million.

🏦 Hedge funds and institutional investors collectively hold 89.07% of the company's outstanding stock.

πŸ’° The company announced a new $5.00 billion share repurchase program authorized by its board.

πŸ“‰ Analysts show mixed sentiment with Wolfe Research downgrading to 'peer perform' while others maintain 'buy' ratings.

πŸ“Š Boston Scientific trades at a P/E ratio of 18.35 with a market cap of $65.20 billion.

πŸ‘” Insiders acquired 9,800 shares valued at $554,012 over the last three months.

πŸ“‰ The stock has a beta of 0.58 and a PEG ratio of 0.84 indicating potential growth efficiency.

πŸ₯ The medical device firm focuses on less-invasive procedures for cardiovascular and other conditions.

Bullish Signals
  • The company announced a $5.00 billion share repurchase program, authorizing the buyback of up to 6.4% of outstanding shares, which typically signals management confidence in undervalued stock.
  • Assetmark Inc. significantly increased its position by 36.9%, adding 39,270 shares to its holdings, indicating strong institutional interest.
  • Bangor Savings Bank grew its stake by 94.7% in the fourth quarter, demonstrating growing confidence from smaller institutional investors.
  • The company maintains a healthy balance sheet with a quick ratio of 1.22 and a current ratio of 1.90.
  • Insiders have been net buyers recently, acquiring 9,800 shares valued at $554,012 in the last three months.
Risk Factors
  • Wolfe Research downgraded Boston Scientific from an 'outperform' rating to a 'peer perform' rating on May 29th.
  • Stifel Nicolaus lowered its price target from $75.00 to $65.00, though it maintained a 'buy' rating.
  • The stock is currently trading below its 50-day moving average of $47.99 and significantly below its 200-day moving average of $65.29.
Full Analysis
Assetmark Inc. increased its stake in Boston Scientific Corporation (NYSE: BSX) by 36.9% during the first quarter, purchasing an additional 39,270 shares to hold a total of 145,679 shares valued at $9.14 million. Several other institutional investors also adjusted their positions, including new stakes from FWL Investment Management, Swiss RE Ltd., and Garton & Associates, each valued around $26,000, while Bangor Savings Bank grew its holding by 94.7% to own 292 shares worth $28,000. The article details Boston Scientific's financial metrics as of the reporting period, noting a market capitalization of $65.20 billion, a price-to-earnings ratio of 18.35, and a beta of 0.58. The stock traded with a 52-week range between $42.20 and $109.50, opening at $43.86 on the reported Tuesday. Key liquidity ratios include a quick ratio of 1.22 and a current ratio of 1.90, alongside a debt-to-equity ratio of 0.42. Corporate developments highlighted include a board-approved share repurchase program authorizing $5.00 billion in buybacks, representing up to 6.4% of outstanding shares, signaling management's view that the stock is undervalued. Insider trading activity saw directors David C. Habiger and Cheryl Pegus purchase shares totaling over $225,000, while analysts provided mixed ratings with a consensus 'Moderate Buy' and an average target price of $79.84.